【レポートの概要（一部）】
1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report
3. Ophthalmic Drugs: World Market 2015-2025
3.1 The World Ophthalmic Drugs Market in 2014
3.2 World Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2015-2025
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2015-2025
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2015-2025
3.5.3 Glaucoma Drugs Market: Sales Forecast 2015-2025
3.5.4 Dry Eye Drugs Market: Sales Forecast 2015-2025
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2015-2025
3.6 How Will Segmental Market Shares Change to 2025?
3.7 CAGR Forecasts of Ophthalmic Drugs Markets From 2014-2025
3.8 Market Attractiveness of Ophthalmic Drugs Markets in 2019
3.9 Market Attractiveness of Ophthalmic Drugs Markets in 2025
3.10 World Ophthalmic Drugs Market: Drivers and Restraints 2015-2025
3.10.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.10.2 World Ophthalmic Drugs Market: Analysis of Restraints
4. Leading US Ophthalmic Drug Manufacturers 2015-2025
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2015?
4.1.1.2 Restasis: Sales Forecast 2015-2025
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2015-2025
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Refresh Brand Products: Sales Forecast 2015-2025
4.1.1.7 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.8 Alphagan/Alphagan P and Combigan: Sales Forecast 2015-2025
4.1.1.9 Acular: New Forms Receiving FDA Approvals
4.1.1.10 Acular: Sales Forecast 2015-2025
4.1.1.11 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Oedema
4.1.2 Allergan: Ophthalmic Product Pipeline
4.1.2.1 Novadur (Intravitreal Brimonidine Implant)
4.1.2.2 AGN 208397 (Beclomethasone Intravitreal Injection)
4.1.2.3 Anti-VEGF DARPins (VEGF Inhibitors)
4.1.3 Allergan: Ophthalmic Revenue Forecast 2015-2025
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2015-2025
4.1.4 Allergan: SWOT Analysis
4.2 Merck Overview
4.2.1 Merck: Exiting the Ophthalmic Drugs Market
4.2.2 Merck: Ophthalmic Product Pipeline
4.2.3 Merck: Ophthalmic Drugs Sales in 2013 and 2014
4.3 Pfizer Overview
4.3.1 Pfizer: Ophthalmic Product Portfolio
4.3.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.3.1.2 Xalatan/Xalacom: Sales Forecast 2015-2025
4.3.2 Pfizer: Ophthalmic Product Pipeline
4.3.3 Pfizer: Revenue Forecast 2015-2025
4.3.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2015-2025
4.3.4 Pfizer: SWOT Analysis
4.4 Regeneron Overview
4.4.1 Regeneron: Ophthalmic Product Portfolio
4.4.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.4.1.2 Eylea: US Sales Forecast 2015-2025
4.4.2 Regeneron: Ophthalmic Product Pipeline
4.4.3 Regeneron: Revenue Forecast 2015-2025
4.4.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2015-2025
4.4.4 FDA Approves Zaltrap (aflibercept)
4.4.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.4.6 Regeneron: SWOT Analysis
4.5 Akorn Overview
4.5.1 Akorn: Ophthalmic Product Portfolio
4.5.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.5.1.2 AzaSite: Sales Forecast 2015-2025
4.5.1.3 Zioptan: Acquired from Merck
4.5.1.4 Zioptan: Sales Forecast 2015-2025
4.5.1.5 Cosopt/Cosopt PF: Acquired from Merck
4.5.1.6 Cosopt/Cosopt PF: US Sales Forecast 2015-2025
4.5.2 Akorn: Revenue Forecast 2015-2025
4.5.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2015-2025
4.5.3 Akorn: SWOT Analysis
5. Leading European Ophthalmic Drug Manufacturers 2015-2025
5.1 Bayer Overview
5.1.1 Eylea: non-US Sales Forecast 2015-2025
5.1.2 Bayer: Revenue Forecast 2015-2025
5.1.2.1 Bayer: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Best-Selling Ophthalmic Drug in 2014
5.2.1.2 Lucentis: Non-US Sales Forecast 2015-2025
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2015-2025
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2015-2025
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2015-2025
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2015-2025
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2015-2025
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2015-2025
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2015-2025
5.3.1.2 Avastin: Will It Remain Off-Label Use for Wet AMD?
5.3.1.3 Avastin: Sales Forecast 2015-2025
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2015-2025
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2015-2025
5.3.4 Roche: SWOT Analysis
5.3.4.1 Lucentis Granted Fourth Approval in the US
6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2015-2025
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2015-2025
6.1.1.2 Hyalein: Santen’s Best Selling Drug in 2014
6.1.1.3 Hyalein: Sales Forecast 2015-2025
6.1.1.4 Cosopt: Non-US Sales Forecast 2015-2025
6.1.1.5 Tapros/Taflotan: Sales Forecast 2015-2025
6.1.1.6 Diquas: Sales Forecast 2015-2025
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2015-2025
6.1.1.9 Trusopt: Non-US Sales Forecast 2015-2025
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2015-2025
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2015-2025
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2015-2025
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2015-2025
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Timoptic: US Sales Forecast 2015-2025
6.3.1.2 Bromday: New Formulation Released
6.3.1.3 Bromday: Sales Forecast 2015-2025
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (BOL 303259-X)
6.3.2.2 MIM-D3 (tyrosine kinase receptor antagonist, Valeant)
6.3.2.3 Brimonidine for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2015-2025
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2015-2025
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
7. Emerging Ophthalmic Drug Manufacturers in 2015
7.1 Pipeline and Other Companies, 2015
7.2 Abbott: Fenofibrate Approved in Australia for Diabetic Retinopathy
7.3 Acucela
7.4 Aerie Pharmaceuticals
7.5 Aerpio Therapeutics: Developing AKB 9778
7.6 Alimera Sciences
7.6.1 Iluvien Gained Recent FDA Approval
7.6.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.7 Altheos
7.8 Amakem
7.9 Ampio Pharmaceuticals
7.10 BioDiem
7.10.1 BDM-E: A High-Value Divestment?
7.11 Can-Fite BioPharma/OphthaliX
7.12 Chengdu Kanghong Pharmaceutical
7.13 Eleven Biotherapeutics
7.14 EyeGate Pharmaceuticals
7.15 Gene Signal
7.15.1 Aganirsen: Preventing Corneal Graft Rejection
7.16 GSK
7.16.1 Darapladib for Diabetic Macular Oedema
7.17 Icon Bioscience
7.18 Lpath
7.18.1 iSONEP: Antibodies Against Bioactive Lipids
7.19 MacuCLEAR
7.19.1 MC 1101: a Potential Therapy for Dry AMD
7.20 Neurotech
7.20.1 Renexus (NT 501) for Dry AMD
7.21 Omeros
7.22 Ophthotech
7.22.1 Will Roche Succeed in Acquiring Fovista?
7.22.2 Fovista: Significant Improvement on Lucentis in Phase 2 Trials
7.22.3 Zimura: Complement C5 Inhibitor
7.23 Otsuka Pharmaceutical
7.24 OXiGENE: Developing Zybrestat for Wet AMD
7.25 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.26 Shire
7.26.1 Lifitegrast (SHP606) for Dry Eye
7.26.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.27 ThromboGenics
7.27.1 Jetrea (ocriplasmin)
7.27.1.1 Jetrea: US Sales Forecast 2015-2025
7.27.2 TB 403: Anti-Placental Growth Factor
8. Qualitative Analysis of the Ophthalmic Drugs Market 2015-2025
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium]
8.1.2 Threat of New Entrants [Low]
8.1.3 Power of Suppliers [Low]
8.1.4 Power of Buyers [Medium]
8.1.5 Threat of Substitutes [Medium]
9. Research Interviews
9.1 Interview with Dan Myers, President and CEO, Alimera Sciences
9.1.1 Alimera Sciences’ Key Products
9.1.2 Expectations for the Launch of Iluvien in the US and EU
9.1.3 Alimera Sciences’ Plans for Growth
9.1.4 Alimera Sciences’ Ophthalmic Pipelines
9.1.5 Challenges in the Ophthalmic Drugs Market
9.1.6 Treatment Change in Retinal Disorders in the Next Decade
9.1.7 Successful Therapies in Ophthalmology in the Next Decade
9.1.8 Trends and Developments in the Ophthalmic Drugs Market
9.2 Interview with Dr. Leigh Hsu, Vice President, Corporate Development and Strategy, Lpath Inc.
9.2.1 Lpath’s Work in Ophthalmology
9.2.2 Progress Update on iSONEP in Clinical Development
9.2.3 Planned Phase 3 Trials in 2015?
9.2.4 Lpath’s Plans for Growth
9.2.5 Main Unmet Needs in Ophthalmology
9.2.6 Promising New Drug Targets in Development
9.2.7 Potential Treatments for Retinal Disorders in the Next Decade
9.2.8 Trends in Ophthalmology: Combination Therapy, Implants, Delivery Methods
9.3 Interview with a Spokesperson for Vanda Pharmaceuticals, Washington DC, US
9.3.1 Commercialising Hetlioz
9.3.2 Future Prospects for Vanda
10. Conclusions
10.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
10.2 The World Ophthalmic Drugs Market in 2014
10.2.1 Leading Ophthalmic Drugs Market Segments
10.2.2 Leading Ophthalmic Drugs
10.2.3 Leading Ophthalmic Drugs Companies
10.3 World Ophthalmic Drugs Market Forecast 2015-2025
10.4 The Future of the Ophthalmic Drugs Market?
10.4.1 Increasing Revenue Concentration among Specialist Companies
10.4.2 The Rise of Generics
10.4.3 Small Companies Can Have a Big Impact
10.4.4 What Will Succeed in the Ophthalmic Drugs Market?
11. Glossary
【レポート販売概要】
■ タイトル：世界の眼疾患治療薬分野における主要な製薬企業分析■ 英文：Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025
■ 発行日：2015年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN503041
■ 調査対象地域：グローバル
- 業務用スープジャーの世界市場2017-2021ABSTRACTAbout Commercial Soup Warmer The global commercial countertop soup warmer market was valued at $289.64 million in 2016, owing to the increase in demand for countertop models with improved features and innovative technologies. For instance, Roband Australia provides countertop soup warmers with cauldron-shaped design and glass-filled nylon outer casing so that the heat transfer is reduced a …
- 2014年戦略提言：イタリアの呼吸器病診断検査市場About This ReportThis new 281-page report from Venture Planning Group presents detailed analysis of the Italian Respiratory Diseases market, including sales forecasts and supplier shares for Adenovirus, Influenza, Legionella, Mononucleosis, Mycoplasma, Pneumonia, RSV and Tuberculosis. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. …
- オートバイ用エアバッグジャケットの世界市場2016-2020About Motorcycle Airbag Jacket Motorcycles are considered one of the most vulnerable modes of transport compared to other vehicles such as passenger cars, trucks, and buses. Most often these machines are built with high-performance engines, which result in a volatile weight-to-torque ratio. These factors make motorcycles the most vulnerable machines on the roads, adding greater risk to the riding …
- 電子コンパスの世界市場予測：フラックスゲート、ホール効果、磁気抵抗技術According to the MarketsandMarkets forecast, the e-compass market size, in terms of value, is expected to grow from USD 808.6 Million in 2015 to USD 2187.1 Million by 2022, at a CAGR of 14.57% between 2016 and 2022. The e-compass has applications across a number of verticals. The portable electronic devices deploy e-compass sensors, primarily as a navigational tool. The huge volume of sales of the …
- Petoro AS：石油・ガスの開発・生産動向及びコスト分析- Q3, 2013Petoro AS Oil & Gas Exploration and Production Operations and Cost Analysis - Q3, 2013 Summary Petoro AS Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for key operational dat …
- 拡声器の世界市場分析：タイプ別（サテライト/サブウーファー、サウンドバー、サブウーファー、インウォール、屋外、マルチメディア）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、ラテンアメリカ、MEA）、セグメント予測、2014-2025The global loudspeaker market is estimated to reach USD 8.48 billion by 2025, according to a new report by Grand View Research, Inc. Increasing middle class population and rising disposable income is expected to propel industry growth. Rising in-home entertainment, decreasing sound quality of the television owing to reduction in size and growing entertainment spending is anticipated to boost indus …
- アメリカの住宅用煙感知器市場2016-2020About Residential Smoke Detectors Market in the US Smoke detectors are devices that sense smoke and indicate the same through signals or alarms, thereby enhancing residential and commercial security. Residential smoke detectors aid in identifying the presence of fire and inhibit it from spreading. These detectors are connected to an alarm system that emits a high-pitched sound to warn residents of …
- ヘルスケア/医療分析ソリューションの世界市場The healthcare analytics market is categorized on the basis of type, component, delivery model, application, end user, and region. Factors such as the rising pressure to curb healthcare costs, big data in healthcare, technological advancements, growing awareness about benefits of analytics, and increase in venture capital investments are driving market growth. On the other hand, the operational ga …
- CMOSイメージセンサーの世界市場展望2017-20276According to Stratistics MRC, the Global CMOS Image Sensors Market is accounted for $9.24 billion in 2017 and is expected to reach $22.81 billion by 2026 growing at a CAGR of 10.6% during the forecast period. Factors such as increasing usage of CMOS sensors in consumer electronics products, rising demand for automobile driver assistance and 4K pixel technology in security & surveillance sector are …
- 世界主要国のシクロスポラ検査（医療機器）市場The report presents a detailed analysis of the Cyclospora diagnostics market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Cyclospora definition, epidemiology and etiology are reviewed. The report provides the 5-year test volume and sales forecasts by country for the following market segments: - Hospitals - Co …
- データセンター用IT装置の世界市場：サーバ、ストレージ、ネットワーク製品About data center IT equipment Enterprises build a data center to house IT equipment such as servers, storage, and network infrastructures. A data center also includes virtual and security appliances for business operational purposes. Most of the modern IT infrastructures such as converged infrastructure offered by vendors are designed to support any business environments. However, data center env …
- 動物診断の世界市場予測（～2022年）：診断装置、消耗品、動物検査技術The veterinary diagnostics market is expected to witness significant growth in the coming years, with a rising demand for animal-derived food products, growing number of livestock and companion animals, rising pet ownership in developed countries, growing demand for pet insurance and rising animal health expenditure, increasing incidence of zoonotic diseases, and growth in the number of veterinary …
- 国境セキュリティの世界市場：バイオメトリクス、ICT、有人車両・無人車両、境界監視The latest 364 page report from business intelligence provider visiongain offers comprehensive analysis of the global border security market. Visiongain assesses that this market will generate revenues of $16.4bn in 2015. Now: Border security is hard to achieve and harder to measure. This is an example of the business critical issue you need to know about - and more importantly, you need to read v …
- 遺伝子組み換え（GM）種子の世界市場2016-2020About Genetic Modification Genetic modification (GM), also called genetic engineering (GE), is a technology where new traits are introduced into an organism by directly manipulating its genetic makeup. For instance, Deoxyribonucleic acid (DNA), is introduced or manipulated through intervention at the molecular level using biotechnology. In the process of this technology, scientists manipulate the …
- ヒトマイクロバイオーム（微生物）の世界市場：プロバイオティクス、プレバイオティクス、食品、医療食、デバイス、薬などNeed for early diagnosis and efficient treatment with microbiome therapy for maintaining healthy lifestyle will boost the human microbiome market The product segment is expected to account for the largest share of the human microbiome market in the coming years. The high growth in this segment is attributed to the expectations to bring promising microbiome products to the market to help individual …
